[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657257":3},{"organization":4,"outcomesModule":7,"designInfo":32,"detailedDescription":36,"studyPopulation":37,"armGroups":38,"interventions":49,"overallOfficials":33,"centralContacts":59,"locations":65,"responsibleParty":83,"collaborators":33,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":33,"eligibilityCriteria":92,"healthyVolunteers":89,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":33,"studyType":99,"phases":33,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":68,"whyStopped":33,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":28},[9,13],{"measure":10,"description":11,"timeFrame":12},"Extraocular Muscle SUVmax on 68Ga-FAPI and 68Ga-DOTATATE PET Imaging","Maximum standardized uptake value will be measured separately in the superior, medial, lateral, and inferior rectus muscles on PET\u002FCT and PET\u002FMR images for each tracer. Values will be summarized by tracer, imaging platform, eye, and participant group.","At each imaging examination performed within the protocol-defined 1-week imaging period",{"measure":14,"description":15,"timeFrame":12},"Extraocular Muscle Target-to-Background Ratio on 68Ga-FAPI and 68Ga-DOTATATE PET Imaging","For each extraocular muscle, target-to-background ratio will be calculated as extraocular muscle SUVmax divided by background SUVmax measured using a 1-cm region of interest in occipital soft tissue. Values will be summarized by tracer, imaging platform, eye, and participant group.",[17,21,25],{"measure":18,"description":19,"timeFrame":20},"Diagnostic Accuracy for Thyroid Eye Disease Activity","Receiver operating characteristic curves will be used to estimate the area under the curve for quantitative 68Ga-FAPI and 68Ga-DOTATATE PET\u002FCT and PET\u002FMR measures in relation to clinically defined thyroid eye disease activity.\n\nRequired confirmation: specify the reference standard and exact Clinical Activity Score threshold used to define active disease before submission.","At completion of imaging and clinical activity assessment within the protocol-defined 1-week period",{"measure":22,"description":23,"timeFrame":24},"Association Between PET Uptake Measures and Clinical Activity Score","Pearson correlation coefficients will be used to assess associations of extraocular muscle SUVmax and target-to-background ratio with Clinical Activity Score.","At completion of imaging and Clinical Activity Score assessment within the protocol-defined 1-week period",{"measure":26,"description":27,"timeFrame":12},"Association Between PET Uptake Measures and Extraocular Muscle Thickness","Pearson correlation coefficients will be used to assess associations of extraocular muscle SUVmax and target-to-background ratio with extraocular muscle thickness measured on anatomic imaging.\n\nRequired confirmation: specify the sequence, measurement plane, muscle-specific rule, and unit for extraocular muscle thickness.",[29],{"measure":30,"description":31,"timeFrame":12},"Visual Positivity of Extraocular Muscle Uptake","Each eye will be classified as positive when any extraocular muscle demonstrates 68Ga-FAPI or 68Ga-DOTATATE uptake greater than background and negative otherwise. At participant level, a participant will be classified as positive when at least one eye is positive. Positivity will be compared between imaging approaches using categorical analyses.",{"allocation":33,"interventionModel":33,"interventionModelDescription":33,"primaryPurpose":33,"observationalModel":34,"timePerspective":35,"maskingInfo":33},null,"COHORT","PROSPECTIVE","This is a prospective, single-center cohort study planned to enroll approximately 50 adults aged 18 to 75 years. The thyroid eye disease cohort will include approximately 30 participants diagnosed according to European Group on Graves' Orbitopathy criteria. The control cohort will include approximately 20 participants without a history of thyroid-related or orbital disease who undergo clinically indicated FAPI or somatostatin receptor PET imaging for another reason; orbital PET\u002FMR acquisition will be added to the existing examination without additional radiation exposure.\n\nParticipants in the thyroid eye disease cohort will undergo 68Ga-FAPI and 68Ga-DOTATATE PET\u002FCT and PET\u002FMR imaging within one week. For each tracer, imaging will begin approximately 50 minutes after intravenous administration of 3 to 5 mCi. PET\u002FCT will include a CT acquisition for attenuation correction and anatomic localization followed by three-dimensional PET acquisition of the head for approximately 5 minutes per bed position. PET\u002FMR will include simultaneous PET acquisition and routine MR sequences, including T1-weighted, T2-weighted, and FLAIR imaging. PET images will be reconstructed using an ordered-subset expectation maximization algorithm and fused with CT or MR images.\n\nNuclear medicine physicians will evaluate images without access to clinical data. Each eye will be visually classified as positive when any extraocular muscle demonstrates uptake greater than background and negative otherwise. For participant-level analysis, a participant will be considered positive when at least one eye is positive. Quantitative analysis will measure maximum standardized uptake value in the superior, medial, lateral, and inferior rectus muscles. A 1-cm region of interest in occipital soft tissue will be used as background. The target-to-background ratio will be calculated as extraocular muscle SUVmax divided by background SUVmax.\n\nClinical information collected from electronic medical records will include age, sex, disease duration, clinical diagnosis, treatment plan, and Clinical Activity Score. Imaging measures will be compared between groups and modalities and will be examined for associations with Clinical Activity Score and extraocular muscle thickness. Receiver operating characteristic analysis will be used to evaluate diagnostic accuracy.","Participants will be selected from adults evaluated in the Department of Nuclear Medicine at the Army Medical Center of PLA between November 2025 and December 2027. The thyroid eye disease cohort will consist of patients meeting European Group on Graves' Orbitopathy diagnostic criteria. The control cohort will consist of patients without thyroid-related or orbital disease who undergo clinically indicated FAPI or somatostatin receptor PET imaging for another reason.",[39,45],{"label":40,"type":33,"description":41,"interventionNames":42},"Group 1 Thyroid Eye Disease Cohort","Adults diagnosed with thyroid eye disease according to European Group on Graves' Orbitopathy criteria. Participants undergo 68Ga-FAPI and 68Ga-DOTATATE PET\u002FCT and PET\u002FMR imaging within one week.",[43,44],"Diagnostic Test: 68Ga-FAPI PET\u002FCT and PET\u002FMR Imaging","Diagnostic Test: 68Ga-DOTATATE PET\u002FCT and PET\u002FMR Imaging",{"label":46,"type":33,"description":47,"interventionNames":48},"Group 2 Control Cohort","Adults without a history of thyroid-related or orbital disease who undergo clinically indicated FAPI or somatostatin receptor PET imaging for another reason. Orbital PET\u002FMR acquisition is added to the existing examination without additional radiation exposure.",[43,44],[50,55],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":33},"DIAGNOSTIC_TEST","68Ga-FAPI PET\u002FCT and PET\u002FMR Imaging","Participants receive 3 to 5 mCi of 68Ga-FAPI intravenously. PET\u002FCT and PET\u002FMR imaging of the head and orbits is performed approximately 50 minutes after injection, with PET acquisition of approximately 5 minutes per bed position. PET\u002FMR includes routine T1-weighted, T2-weighted, and FLAIR sequences. The exact FAPI compound should be added if specified by the radiopharmacy documentation.\n\nRequired confirmation: the protocol does not identify the specific FAPI compound, such as FAPI-04.",[40,46],{"type":51,"name":56,"description":57,"armGroupLabels":58,"otherNames":33},"68Ga-DOTATATE PET\u002FCT and PET\u002FMR Imaging","Participants receive 3 to 5 mCi of 68Ga-DOTATATE intravenously. PET\u002FCT and PET\u002FMR imaging of the head and orbits is performed approximately 50 minutes after injection, with PET acquisition of approximately 5 minutes per bed position. PET\u002FMR includes routine T1-weighted, T2-weighted, and FLAIR sequences.",[40,46],[60],{"name":61,"role":62,"phone":63,"phoneExt":33,"email":64},"Xiao Chen, PH .D","CONTACT","15922970174","xiaochen229@tmmu.edu.cn",[66],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"Daping Hospital","RECRUITING","Chongqing","Chongqing Municipality","400010","China","CN",{"type":75,"coordinates":76},"Point",[77,78],106.55771,29.56026,{"lat":78,"lon":77},[81],{"name":82,"role":62,"phone":63,"phoneExt":33,"email":64},"Xiao Chen, PH.D",{"type":84,"investigatorFullName":85,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Xiao Chen","Director, Department of Nuclear Medicine","100657257","comparative-evaluation-of-68ga-fapi-and-68ga-dotatate-petct-and-petmri-in-thyroid-eye-disease-100657257",false,"NCT07835607","Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET\u002FCT and PET\u002FMRI in Thyroid Eye Disease","Inclusion Criteria:\n\n* For the thyroid eye disease cohort: diagnosis of thyroid eye disease according to European Group on Graves' Orbitopathy criteria.\n* For the thyroid eye disease cohort: scheduled to undergo 68Ga-FAPI PET\u002FCT and PET\u002FMR and 68Ga-DOTATATE PET\u002FCT and PET\u002FMR within one week.\n* For the control cohort: clinically recommended to undergo FAPI or somatostatin receptor PET imaging for another reason, with no history of thyroid-related disease or orbital disease; orbital PET\u002FMR is added to the existing examination without additional radiation exposure.\n\nExclusion Criteria:\n\n* Previous bilateral orbital surgery.\n* Treatment with glucocorticoids, monoclonal antibodies, or radiotherapy within the previous month.\n* Inability to remain supine.\n* Contraindication to MRI, including incompatible metallic implants or claustrophobia.\n* Planning pregnancy, currently pregnant, or breastfeeding.","ALL","18 Years","75 Years",{"count":97,"type":98},50,"ESTIMATED","OBSERVATIONAL","Thyroid eye disease is an autoimmune disorder that can cause inflammation and fibrosis of the extraocular muscles and orbital tissues. Accurate assessment of disease activity is important for treatment planning, but commonly used clinical scores and conventional imaging each have limitations.\n\nThis prospective single-center cohort study will evaluate two molecular imaging approaches, gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET\u002FCT and PET\u002FMR and gallium-68 DOTATATE somatostatin receptor PET\u002FCT and PET\u002FMR, in adults with thyroid eye disease and in a control group without thyroid-related or orbital disease. The study will compare visual and quantitative imaging findings, including maximum standardized uptake value and target-to-background ratio in the extraocular muscles, and examine their associations with clinical activity score and extraocular muscle thickness. The study aims to characterize the ability of these imaging methods, separately and in combination, to assess thyroid eye disease activity.",[102],"Thyroid Eye Disease",[104,105,106,102],"FAPI","SSTR","PET","2026-09-16",{"date":109,"type":110},"2026-09-23","ACTUAL",{"date":112,"type":110},"2025-11-14",{"date":114,"type":98},"2027-12-31",{"name":5,"class":6},1]